Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

Rekombinanter RSV (Palivizumab Biosimilar) Antikörper

Reaktivität: Human FACS, in vivo Wirt: Maus Monoclonal unconjugated Recombinant Antibody
Produktnummer ABIN7208214
  • Target Alle RSV (Palivizumab Biosimilar) Produkte
    RSV (Palivizumab Biosimilar)
    Antikörpertyp
    Recombinant Antibody
    Reaktivität
    Human
    Wirt
    • 1
    • 1
    Maus
    Klonalität
    • 2
    Monoklonal
    Konjugat
    • 2
    Dieser RSV (Palivizumab Biosimilar) Antikörper ist unkonjugiert
    Applikation
    • 1
    • 1
    • 1
    Flow Cytometry (FACS), In vivo Studies (in vivo)
    Verwendungszweck
    Palivizumab Biosimilar, RSV Monoclonal Antibody
    Spezifität
    The monoclonal antibody palivizumab biosimilar specifically binds to an epitope in the A antigenic site of the F protein of RSV (respiratory syncytial virus).
    Produktmerkmale
    Recombinant Humanized IgG1 Monoclonal Antibody.
    Aufreinigung
    Protein A affinity column
    Reinheit
    > 95% by SDS-PAGE under reducing conditions and HPLC.
    Sterilität
    0.2 μm filtered
    Endotoxin-Niveau
    < 1 EU per 1 mg of the protein by the LAL method.
    Immunogen
    The monoclonal antibody palivizumab biosimilar was produced in the palivizumab biosimilar CHO stable cell line.
    Isotyp
    IgG1 kappa
  • Applikationshinweise
    ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by palivizumab.
    Beschränkungen
    Nur für Forschungszwecke einsetzbar
  • Format
    Liquid
    Konzentration
    1 mg/mL
    Buffer
    PBS, pH 7.4, no stabilizers or preservatives.
    Konservierungsmittel
    Without preservative
    Handhabung
    Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
    Lagerung
    -20 °C
    Informationen zur Lagerung
    12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
    Haltbarkeit
    12 months
  • Target
    RSV (Palivizumab Biosimilar)
    Abstract
    RSV (Palivizumab Biosimilar) Produkte
    Substanzklasse
    Biosimilar
    Hintergrund
    Palivizumab, a humanized anti-RSV (respiratory syncytial virus) monoclonal antibody, targets an epitope in the A antigenic site of the F protein of RSV, inhibiting its entry into the cell and thereby preventing infection.
Sie sind hier:
Kundenservice